FEMALE INFERTILITY HAS MANY FACTORS

Infertility means being unable to get pregnant after at least one year of trying (or six months if the woman is over age 35). Infertility results from female factors about one-third of the time and male factors about one-third of the time. If a woman keeps having miscarriages, this is also called infertility. Female infertility contributes to nearly 50 percent of all infertility cases.

….FULL ARTICLE

UNDERSTANDING DEPRESSION IN WOMEN

Depression is a common but serious mood disorder. It reveals itself through symptoms such as hopelessness, pessimism, irritability, guilt, helplessness and decreased energy or fatigue lasting at least two weeks or longer. About twice as many women as men experience depression. Several factors may increase a woman’s risk of depression.

….FULL ARTICLE

RECOVERING FROM A HEART ATTACK

What happens now?  That is a question you could ask after surviving a heart attack.  How do you take care of yourself afterwards so that there is no repeat?  According to Family Doctor (www.familydoctor.org), a heart attack happens when part of the heart muscle is damaged or dies because it does not receive enough oxygen. The blood in the coronary arteries carries oxygen to the heart muscle. Most heart attacks occur when a blockage slows down or stops the flow of blood through these arteries.

….FULL ARTICLE

Use the buttons below to scroll through more great articles on health and wellness issues

MORE ARTICLES

Be Sociable, Share!

Share on Facebook Share on Twitter Share on Delicious Share on Digg Share on Google Bookmarks Share on LinkedIn Share on LiveJournal Share on Newsvine Share on Reddit Share on Stumble Upon Share on Tumblr

MORE FEATURE ARTICLES

CONTACT INFORMATION

© Health & Wellness Magazine - All rights reserved | Designed and Maintained by PurplePatch Innovations

MORE FROM ROCKPOINT PUBLISHING

HEALTH & WELLNESS MAGAZINE

HOME | FEATURE ARTICLES | COLUMNS | DIGITAL ISSUES | CALENDAR | RACE RUNNING CALENDAR | ABOUT | CONTACT

subscribe to Health & Wellness


The results of two new randomized and controlled mental health research studies demonstrated that just one dose of psilocybin produces significant long-term improvements in patients with anxiety and depression. These findings, recently published in The Journal of Psychopharmacology, are potentially beneficial for individuals who are troubled by anxiety and depression.


Psilocybin is a hallucinogenic substance obtained from certain types of mushrooms indigenous to tropical and subtropical regions of South America, Mexico and the United States. Fifty-one adults participated in the double-blind crossover study at Johns Hopkins University. New York University was the second site. Stephen Ross, M.D., principal investigator of the NYU study and director of substance abuse services in the Department of Psychiatry at Langone Medical Center, said all patients received targeted counseling plus a 0.3 mg/kg dose of psilocybin at one of two treatment sessions. A vitamin placebo at the other session realized 80 percent of the subjects experienced a significant reduction in anxiety and depressive symptoms after six months. Furthermore, 80 percent of the subjects realized clinically significant decreases in symptomology six months after their final treatment session, suggesting there may be longer term benefits with less need for medication.


Further research with larger samples needs to be conducted,

INNOVATIVE RESEARCH FINDINGS SUGGEST NEW DIRECTION IN MENTAL HEALTH CARE

but it is clear these initial findings raise the issue that psilocybin holds true potential for treating anxiety and depression in patients with this diagnosis. These results represent a dramatic step forward in the mental health profession’s efforts to help some of the most seriously affected patients needing a more effective protocol of care and treatment for anxiety and depression.


Sources and Resources:


•  Hallucinogenic drug psilocybin eases existential anxiety in people with life threatening cancer. Baltimore, MD: Johns Hopkins University School of Medicine; December 1, 2016.

•  Single dose of hallucinogenic drug psilocybin relieves anxiety and depression in patients with advanced cancer. New York, NY: New York University Langone Medical Center; December 1, 2016.

DR. THOMAS W. MILLER, PH.D, ABPP

Thomas W. Miller, Ph.D., ABPP, is a professor emeritus and senior research scientist, Center for Health, Intervention and Prevention, University of Connecticut; retired service chief from the VA Medical Center; and tenured professor in the Department of Psychiatry, College of Medicine, University of Kentucky.

more articles by Dr thomas w. miller